Nimbus Therapeutics Enters into Strategic Partnership with Charles River Laboratories to Advance New Therapeutic Programs
April 05 2017 - 08:00AM
Business Wire
Nimbus Therapeutics and Charles River Laboratories
International, Inc. (NYSE: CRL) today launched a multi-year
strategic partnership to advance new programs spanning the disease
areas of immunology, metabolic disorders and oncology from the
discovery phase through to Investigational New Drug (IND)
submission.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170405005195/en/
The collaboration announced today expands upon the long-standing
relationship between Nimbus and Charles River to work on targets of
critical importance. Nimbus, a biotechnology company applying deep
computational chemistry expertise throughout drug discovery and
development, collaborates closely with Charles River as part of its
unique outsourcing model to design breakthrough medicines.
The combined team will advance programs through discovery and
preclinical development, taking advantage of Charles River’s
capabilities from initial hit identification through all aspects of
discovery optimization, including medicinal chemistry and
pharmacology, and ultimately, into safety testing and IND
submission. Under the terms of the agreement, Charles River is
eligible to receive potential milestone payments from Nimbus for
certain undisclosed program advancements.
“We expect that our portfolio of discovery and safety assessment
expertise, together with Nimbus’ impressive track record in using
computational chemistry to accelerate drug discovery, will result
in additional speed and scale to their future pipeline,” said James
Foster, Chairman, President and Chief Executive Officer of Charles
River.
Don Nicholson, Ph.D., Chief Executive Officer of Nimbus, added:
“Charles River’s broad experience in discovery research across
multiple therapeutic areas, as well as background in safety
assessment, makes them a highly valued contributor to Nimbus’ drug
discovery efforts. We’re looking forward to furthering our
collaboration with Charles River as we work together to progress
the most promising targets through discovery and preclinical
development.”
About Nimbus Therapeutics
Nimbus Therapeutics is a biotechnology company headquartered in
Cambridge, Massachusetts (USA). With its breakthrough computational
chemistry platform, enabled through its privileged partnership with
co-founder, Schr�dinger, Inc., Nimbus is pioneering the application
of computational chemistry to design treatments for substantial and
underserved human diseases. The company’s focus on metabolic
diseases, cancer and immune-inflammatory disorders reflects the
mechanistic relationship between these disorders, and Nimbus’
ability to rapidly tackle well validated targets as well as those
that have proven intractable to the approaches taken by others in
the pharmaceutical and biotechnology industry, resulting in
medicines with high potency, selectivity and other desirable
drug-like properties. To learn more, please visit
www.nimbustx.com.
About Charles River
Charles River provides essential products and services to help
pharmaceutical and biotechnology companies, government agencies and
leading academic institutions around the globe accelerate their
research and drug development efforts. Our dedicated employees are
focused on providing clients with exactly what they need to improve
and expedite the discovery, early-stage development and safe
manufacture of new therapies for the patients who need them. To
learn more about our unique portfolio and breadth of services,
visit www.criver.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170405005195/en/
Media Contacts:Nimbus TherapeuticsTen Bridge
CommunicationsDan Quinn,
781-475-7974TBCnimbus@tenbridgecommunications.comorCharles
RiverAmy Cianciaruso, 781-222-6168Corporate Vice President,
Public Relationsamy.cianciaruso@crl.comorInvestor
Contacts:Charles RiverSusan E. Hardy,
781-222-6190Corporate Vice President, Investor
Relationssusan.hardy@crl.com
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Charles River Laboratories (NYSE:CRL)
Historical Stock Chart
From Mar 2023 to Mar 2024